Shuo Han

Shuo Han, PhD, is a seasoned professional in the field of oncology, currently serving as a Senior Medical Science Liaison at Jazz Pharmaceuticals since September 2020, focusing on solid tumors. Previous experience includes a role as a Medical Science Liaison at Daiichi Sankyo, Inc. from March 2018 to September 2020, where responsibilities encompassed managing key opinion leaders in the Texas and surrounding regions, participating in oncology drug launches such as Turalio and Enhertu, and supporting clinical trials in areas including hematology and various cancers. Shuo also held the position of Senior Clinical Research Program Coordinator at MD Anderson Cancer Center from September 2015 to February 2018, and served as a Research Fellow at the University of Aberdeen, contributing to studies on familial Hodgkin lymphoma from 2013 to 2014. Educational background includes a PhD in Cell/Cellular and Molecular Biology from Baylor College of Medicine, along with a Bachelor of Science in Biochemistry and Genetics from Texas A&M University.